FINHUB Insights

RVTY · Q2 FY25 · Mar 31 – Jun 29, 2025

Revvity Q2 FY25: where the revenue came from and where it went

Revvity Q2 FY25: revenue $0.7B (+4% year over year). Net profit $0.1B. Largest cohort Life Sciences $0.4B. The whole income statement as a sankey diagram from the SEC filing.

Period
Mar 31 – Jun 29, 2025
Reported
Aug 5, 2025 10-Q
Sankey diagram of Revvity's income statement for Q2 FY25: revenue of $0.7 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$0.7B +4% year over year
Gross profit$0.4B 55% margin
Operating profit$0.1B 13% margin
Net profit$0.1B 7% margin

The numbers

All figures in billions of U.S. dollars, for Q2 FY25 (period ends Jun 29, 2025).
ItemValueShare of revenueYear over year
Revenue 0.7 100% +4%
Life Sciences 0.4 57% +5%
Diagnostics 0.4 57% +3%
Cost of revenue−0.343%
Gross profit0.455% margin−1pp
Research & development−0.17%+0pp
SG&A−0.235%−2pp
Operating profit0.113% margin+0pp
Net profit0.17%−1pp
Filing on EDGAR More quarters of RVTY

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters